Search

Search Constraints

You searched for: Author/Creator Chekerov, Radoslav

Search Results

1. 2022-RA-1192-ESGO NOGGO ov44 – PERCEPTION What is the role of immunotherapy in low grade ovarian cancer? A NOGGO phase II trial of pembrolizumab in combination with chemotherapy in recurrent low-grade serous ovarian cancer. (20th October 2022)

2. 2022-RA-1725-ESGO Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer- results of a multicentre NOGGO phase I and II study (TOPAZ). (20th October 2022)

3. 2022-RA-672-ESGO Comparison of quality of life in patients with platinum-sensitive recurrent ovarian, fallopian tube and peritoneal cancer treated with trabectedin plus pegylated liposomal doxorubicin (PLD) or standard platinum-based therapy: Data look of the NOGGO S16/COMPASS trial. (20th October 2022)

4. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). Issue 4 (5th March 2020)

6. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients. Issue 8 (1st October 2017)

7. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients. Issue 8 (October 2017)

8. Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study. Issue 6 (30th March 2022)

9. Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium—OVCAD. Issue 2 (1st February 2013)

10. Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV: Analysis of the OVCAD Data. Issue 3 (1st March 2012)